Curative Resection for Metachronous Pulmonary Metastases from Colorectal Cancer: Analysis of Survival Rates and Prognostic Factors

Myong Hoon Ihn; Duck-Woo Kim; Sukki Cho; Heung-Kwon Oh; Sanghoon Jheon; Kwhanmien Kim; Eun Shin; Hye Seung Lee; Jin-Haeng Chung; Sung-Bum Kang

doi:10.4143/crt.2015.367

Articles

Page Path: HOME > Cancer Res Treat > Volume 49(1); 2017 > Article

Original Article Curative Resection for Metachronous Pulmonary Metastases from Colorectal Cancer: Analysis of Survival Rates and Prognostic Factors: Myong Hoon Ihn, MD¹, Duck-Woo Kim, MD, PhD^1,, Sukki Cho, MD, PhD², Heung-Kwon Oh, MD¹, Sanghoon Jheon, MD, PhD², Kwhanmien Kim, MD, PhD², Eun Shin, MD³, Hye Seung Lee, MD, PhD³, Jin-Haeng Chung, MD, PhD³, Sung-Bum Kang, MD, PhD¹; Cancer Research and Treatment : Official Journal of Korean Cancer Association 2017;49(1):104-115.
DOI: https://doi.org/10.4143/crt.2015.367
Published online: May 9, 2016

¹Department of Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea

²Department of Thoracic and Cardiovascular Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea

³Department of Pathology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea

Correspondence: Duck-Woo Kim, MD, PhD Department of Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, 82 Gumi-ro 173beon-gil, Bundang-gu, Seongnam 13620, Korea
Tel: 82-31-787-7101 Fax: 82-31-787-4055 E-mail: kdw@snubh.org

• Received: October 1, 2015 • Accepted: April 18, 2016

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

10,944 Views
201 Download
27 Web of Science
21 Crossref
28 Scopus

prev next

Full Article

Download PDF

Abstract

Purpose
Prognostic factors in patients with pulmonary metastases (PM) from colorectal cancer (CRC) are still controversial. This study assessed oncologic outcomes and prognostic factors in patients with metachronous PM from CRC.
Materials and Methods
Between June 2003 and December 2011, 122 patients with CRC underwent curative resection of PM detected at least 4 months after CRC resection. Clinico-pathological factors selected from the prospectively maintained database were analyzed retrospectively.
Results
The median disease-free interval (DFI) between resection of the primary tumor and detection of PM was 22.0 months (range, 4 to 85 months). Solitary PM were detected in 77 patients (63.1%), with a median maximal tumor diameter of 12.0 mm (range, 2 to 70 mm). Of 52 patients who underwent mediastinal lymph node (LN) dissection, eight patients had LN involvement. Five-year overall survival and disease-free survival (DFS) rates after initial pulmonary metastasectomy were 66.4% and 50.9%, respectively. DFI, mediastinal LN involvement, and the number and distribution of PM were significantly prognostic factors for DFS. In multivariable analysis DFI ≥ 12 months, solitary lesion, and absence of mediastinal LN involvement were independently prognostic for DFS. Of the 122 patients, 48 patients (39.3%) developed recurrent PM a median 13.0 months after initial pulmonary metastasectomy. Recurrent DFI was independently prognostic of DFS in patients who underwent repeated pulmonary metastasectomy.
Conclusion
There is a potential survival benefit for patients with metachronous PM from CRC who undergo pulmonary metastasectomy, even those with recurrent PM. Pulmonary metastasectomy should be considered in selected patients, particularly those with longer DFI, solitary lesions, and absence of mediastinal LN involvement.
Key words: Pulmonary metastasis, Colorectal neoplasms, Disease-free interval, Metastasectomy

Introduction

Colorectal cancer (CRC) is a common cause of cancer-related death, with increased incidence over the past 25 years [1,2]. Despite advances in treatment, it is expected that more than 50% of patients undergoing resection for CRC will experience disease recurrence [3,4]. Pulmonary metastases (PM) have been reported in approximately 10% to 25% of patients with CRC [5,6]. Patients who underwent curative resection of CRC and isolated PMs had 5-year overall survival (OS) rates of 27% to 68% [6-8], whereas patients with untreated metastatic disease had a median survival of less than 10 months and a 5-year survival rate of less than 5% [9,10].

Surgical resection combined with adjuvant chemotherapy is the current treatment of choice for patients with resectable PM, whereas chemotherapy is the treatment of choice for patients with unresectable PM [11]. Despite development of several novel chemotherapeutic and targeted agents for treatment of metastatic CRC, which might prolong disease-free survival (DFS) and OS, the long-term results have been less than satisfactory in patients with unresectable PM [12]. Surgical resection has been accepted as the only radical treatment available for PM and has shown benefits in cases where metastases are confined to the lungs and complete resection (R0) is possible [13,14]. However, the recurrence rate after pulmonary metastasectomy is still as high as 68%, with the remaining lung being the most common site of recurrence [6]. Therefore, identification of factors prognostic of the outcomes of pulmonary metastasectomy in patients with PM from CRC is important.

Many factors have been reported to show association with the prognosis of patients with PM from CRC who undergo pulmonary metastasectomy, including number of pulmonary lesions, patient age, stage of the primary tumor, history of liver resection, maximum tumor size, histology of the primary tumor, disease-free interval (DFI) between primary CRC surgery and detection of PM, and carcinoembryonic antigen (CEA) concentration [2,6,13]. However, these studies included small numbers of patients, patients who underwent R1 and/or R2 resection, or patients with both synchronous and metachronous lesions, and few studies have assessed therapeutic strategies in patients who develop recurrent PM after the first pulmonary metastasectomy.

This study was therefore designed to determine prognostic factors of survival in patients who underwent complete resection for metachronously developed PM. In addition, outcomes and factors prognostic of repeated pulmonary metastasectomy for recurrent PM were analyzed.

Materials and Methods

In this study patients who underwent curative pulmonary resection for metachronous PM from CRC at Seoul National University Bundang Hospital between June 2003 and June 2011 were analyzed retrospectively. Curative pulmonary resection was defined as histologically-proven complete resection for isolated pulmonary metastatic lesions, confined to the lungs without local or extrapulmonary recurrence on computed tomography (CT) scans of the chest, abdomen, and pelvis and positron emission tomography (PET) of the entire body. Metachronous PM was defined as a new lesion detected at least 4 months after curative CRC surgery, as reported in a previous study [15]. Patients with synchronous PM and those who underwent pulmonary metastasectomy with positive margins (R1 resection) or gross residual disease (R2 resection), or those with evidence of distant metastasis or concurrent malignancy at pretreatment work-up, except for resectable hepatic metastases, were excluded.

Patients were followed up after CRC surgery according to our postoperative surveillance protocol. Patients underwent physical examination and measures of serum CEA levels every 3 months for 2 years, and then every 6 months for 5 to 8 years. Contrast-enhanced CT scans of the chest, abdomen, and pelvis were performed every 3 to 6 months during the first 2 years, and then every 6 to 12 months thereafter, and total colonoscopy was performed every 1 to 2 years. PET-CT was selectively performed if needed, mainly in patients with suspected recurrence. Diagnosis of PM was based on imaging findings on chest X-ray or CT. Indeterminate lesions detected in the lungs after CRC surgery were discussed by a multi-disciplinary team (MDT), consisting of a colorectal surgeon, thoracic surgeon, radiologist, pathologist, and medical oncologist; assessment by chest CT was performed 3 months later. Lesions that became larger and more prominent were defined as PM. The onset of PM in those patients was defined as the time after CRC surgery when the new pulmonary nodules were first detected.

Treatment decisions were made by the MDT. The selection criteria for pulmonary metastasectomy were defined as described previously [16]: (1) no evidence of uncontrolled primary site, (2) no evidence of extrathoracic metastasis, (3) chest CT showing that complete resection was possible regardless of the number of lesions, (4) tumors in the bilateral thorax not considered a contraindication, and (5) patient’s general condition should be able to tolerate surgery, with remaining respiratory function sufficient for normal daily life. Further resection in patients who developed additional PM was performed according to the above-mentioned criteria. Pulmonary metastasectomy of metastatic nodules consisted of non-anatomical resection (precision excision and wedge resection) and anatomical resection (segmental resection and lobectomy). Precision excision was defined as nonanatomical resection by application of electrocautery just beneath the lesion, leaving essentially all normal lung tissue. Wedge resection through thoracotomy or video-assisted thoracic surgery was the procedure of choice, although lobectomy was performed on metastatic lesions located deep within the pulmonary parenchyma. Mediastinal lymph node (LN) dissection was performed selectively.

Surgical specimens were assessed histologically. All specimens were fixed in formalin and sectioned in the oblique coronal plane to include the largest plane of the tumor, and all sections were stained with hematoxylin and eosin, followed by examination by light microscopy.

Collection and analysis of data was performed in June 2014. Factors recorded included patient age, sex, body mass index, primary tumor location, presence of liver metastases, tumor staging, histology of the primary tumor, neoadjuvant and/or adjuvant chemoradiotherapy for primary CRC, DFI between initial resection of the primary CRC and detection of PM, number and maximal diameter of PMs, distribution of PMs, types of resection performed, mediastinal LN dissection and involvement, chemotherapy after pulmonary metastasectomy, and OS and DFS. In addition, OS and DFS in patients with recurrent PM, defined as a new pulmonary nodule or development of a tumor after initial pulmonary metastasectomy, were measured from the time of the first pulmonary metastasectomy to the time of death or recurrence. DFI and recurrent DFI were dichotomized according to < 12 months and ≥ 12 months, as reported in a previous study [17]. The sizes of all metastatic tumors were dichotomized as ≤ 20 mm and > 20 mm.

The Kaplan-Meier method and log rank test were used for evaluation of the prognostic effect of each variable on survival and l multivariable Cox proportional hazards regression analysis was performed for analysis of factors related to survival. Patients were subgrouped according to factors significantly prognostic of DFS, and rates of survival and recurrent PM in the subgroups were compared. Categorical variables were analyzed using the chi-squre test or Fisher exact test, and continuous variables were compared using Student’s t test. p-values ≤ 0.05 were considered statistically significant. Statistical analyses were performed using SPSS ver. 18.0 (SPSS Inc., Chicago, IL). This study was approved by the Ethics Review Board at Seoul National University Bundang Hospital, Korea.

Results

Between June 2003 and June 2011, 2,529 patients underwent curative CRC surgery at our hospital. Of these, 167 patients (6.6%) developed PM, including 54 patients (2.1%) with synchronous and 113 patients (4.5%) with metachronous lesions. Of the latter 113 patients, 94 patients underwent pulmonary metastasectomy for metachronous PM, and 36 of 39 referred patients with metachronous PM who underwent CRC surgery at other hospitals underwent curative pulmonary metastasectomy at our hospital during the study period. Following exclusion of eight patients who underwent R1 or R2 resection, 122 patients were eligible for analysis.

There were significant differences in baseline characteristics between patients with synchronous PM and those with metachronous PM according to tumor stage of CRC, adjuvant therapy for CRC, number of prior regimens, and number and distribution of PM (Table 1). The median interval between primary CRC surgery and pulmonary metastasectomy in patients with synchronous and metachronous PM was 1.5 months (range, 0 to 25 months) and 24.0 months (rang, 4 to 86 months), respectively. However, there was no difference in survival rate between the two groups; the 5-year OS rates were 65.6% and 66.9% (p=0.57), respectively; the 5-year DFS rates were 40.8% and 50.9% (p=0.26),respectively.

The mean age of patients with metachronous PM was 61.3±11.2 years, and 83 patients (68.0%) were male. Serum CEA level was available in 102/122 (83.6%) patients, and missing in 20 cases because the patients had been referred. Of these, 64 patients had a normal serum CEA level, whereas 38 patients had a high serum CEA level. The primary CRC was located in the colon in 55 patients (45.1%), and 14 patients (11.5%) underwent curative hepatic resection for liver metastases during CRC surgery. The median DFI was 22.0 months (range, 4 to 85 months). Seventy-seven patients (63.1%) had solitary PM, and the median maximum tumor size was 12.0 cm (range, 2 to 70 cm). The types of pulmonary resection included precision excision (28.7%), wedge resection (45.1%), segmental resection (9.8%), and lobectomy (16.4%). Mediastinal LN dissection was performed in 52 patients (42.6%), and eight of 52 patients (15.4%) had mediastinal LN involvement. A total of 111 patients (91.0%) received chemotherapy after pulmonary metastasectomy; 97 patients (79.5%) received a cytotoxic agent only, and 14 patients (11.5%) received a cytotoxic agent with a targeted agent (Table 1).

The median follow-up period after the first pulmonary metastasectomy was 27.5 months (range, 1 to 104 months). A total of 48 patients (39.3%) had developed recurrent PM after initial pulmonary metastasectomy, including 39 patients with recurrent pulmonary metastases confined to the lungs and nine patients with multiple systemic metastases. Of 39 patients with pulmonary recurrence, only 10 patients had recurrences at previous resection sites. Pulmonary recurrence in the ipsilateral lung was detected in 12 patients, contralateral in 13, and bilateral in four. The 5-year DFS rate after initial pulmonary metastasectomy was 50.9%. In univariable analysis, DFI, number of PMs, distribution of PMs, and mediastinal LN involvement were significantly prognostic of DFS. In multivariable analysis, DFI ≥ 12 months, solitary lesions, and absence of mediastinal LN were independently prognostic of DFS (Table 2).

The 5-year OS rate in patients with recurrent PM was 56.3%, and the median DFI for recurrent PM after the first pulmonary metastasectomy was 13.0 months (range, 1 to 38 months). Of the 48 patients with recurrent PM, 39 patients (81.2%) underwent repeated pulmonary metastasectomy. In univariable analysis DFI of recurrent PM, number of PMs, and distribution of metastases were significantly prognostic of OS, whereas mediastinal LN involvement and chemotherapy after pulmonary metastasectomy were not significantly prognostic of OS. In multivariable analysis, DFI of recurrent PM was the only factor independently prognostic of OS in patients who underwent repeat pulmonary metastasectomy (Table 3).

Patients were divided into two subgroups according to DFI and number of PMs. The high-risk group (n=70) was defined as patients with DFI < 12 months, or multiple lesions, or mediastinal LN involvement, and the low-risk group (n=52) as patients with DFI ≥ 12 months, solitary lesions, and absence of mediastinal LN involvement. The median DFI in the high- and low-risk groups was 15.0 months (range, 4 to 83 months) and 28.0 months (range, 13 to 85 months), respectively. The median number of PMs was 2.0 (range, 2 to 14) in the high-risk group. Of 70 patients (54.3%) in the high-risk group, 38 patients developed recurrent PM after initial pulmonary metastasectomy compared with 10 of 52 (19.2%) in the low-risk group (p < 0.001). Development of recurrent PM occurred within 12 months in 16 of 38 patients (42.1%) in the high-risk group, compared with three of 10 (30.0%) in the low-risk group. The high- and low-risk groups differed significantly in stage of CRC, distribution of PM and recurrent PM, whereas there was no significant difference in the percentage who received adjuvant chemotherapy (Table 4). OS and DFS rate also showed significant difference in the two groups (Fig. 1).

Discussion

This study demonstrates the potential benefit of curative pulmonary metastasectomy for survival in patients with metachronous PM from CRC. Our results showed that DFI, number of pulmonary lesions, and mediastinal LN involvement were independent prognostic factors in patients with CRC who underwent curative pulmonary metastasectomy. In addition, better survival rates were observed for patients with recurrent PM ≥ 12 months compared to those who developed recurrent PM < 12 months after pulmonary metastasectomy.

We observed 5-year OS and DFS rates of 66.4% and 50.9%, respectively; this OS rate is at the high end of the range of previously reported 5-year OS rates (30% to 68%) [18]. However, the current study only included patients with metachronous lesions who underwent R0 resection. These findings suggest that patients should be carefully selected by strict multimodal assessment of the probability of R0 pulmonary metastasectomy.

Various factors, including number of pulmonary lesions, patient age, stage of the primary tumor, history of liver resection, maximum tumor size, histology of the primary tumor, DFI, and CEA level, have been associated with the prognosis of patients who undergo pulmonary metastasectomy [2,7,14]; however, the results remain controversial because of the heterogeneity of selection criteria and variations in multimodal treatment [19]. Therefore, only patients with metachronous PM who underwent R0 resection were assessed, since it is important to determine whether pulmonary resection offers a chance of cure.

There is no definite consensus regarding synchronous and metachronous PM. In previous studies lesions detected prior to or within 3 months after CRC surgery were defined as synchronous PM [15], whereas in some studies lesions detected at least 6 months after the primary resection were defined as synchronous PM [14]. The first opportunity for follow-up imaging study usually occurred at 3 months after the primary CRC surgery; therefore, metachronous PM was defined as a new lesion detected at least 4 months after primary CRC surgery.

DFI has been reported to be prognostic of pulmonary metastasectomy for PM from CRC [14]; however, various cut-off values have been used to define short DFI, and the correlation between DFI and survival rate was not determined in several studies [7,20]. The mechanism underlying this finding may be related to the time of detection of disease progression, or earlier metastasis may represent a more disseminated disease and tendency to spread than later metastasis [21]. Our results showed that DFI was independently prognostic of pulmonary metastasectomy for PM. Therefore, careful follow-up is required after pulmonary metastasectomy for patients who develop PM less than 1 year after primary tumor resection.

Similar to previous studies, we observed significantly better prognosis for patients with a solitary pulmonary lesion than for those with multiple lesions [8], although several studies found no significant association between prognosis and number of PMs [4,13]. Multiple lesions may increase the likelihood of widespread undetected tiny nodules throughout the lungs or even in other distant organs. Therefore, meticulous preoperative staging for PM is critical in detection of occult metastatic lesions.

Several studies suggested an association of mediastinal LN involvement with an increased risk of death [6,13] and a meta-analysis showed poor 5-year survival in the group with LN involvement (range, 0% to 33.5%) compared to those with no thoracic LN metastases (range, 38.7% to 71%) [19]. However, mediastinal LN was not routinely performed in most studies. Our results showed that mediastinal LN involvement was a significantly prognostic factor for DFS in univariable and multivariable analysis, although there were no differences in DFS between patients who underwent mediastinal LN dissection and those who did not. Therefore, we suggest that mediastinal LN dissection could be performed in patients with expected LN involvement who show an enlarged LN on preoperative chest CT or hypermetabolic lesion on PET-CT.

This study also identified a subgroup of patients, based on DFI and number of PMs, who are expected to benefit most from pulmonary metastasectomy. A significantly higher recurrent PM rate was observed in the high risk group compared with the low-risk group (54.3% vs. 19.2%, p < 0.001), suggesting that pulmonary metastasectomy might have the greatest benefit in the low-risk group. Careful attentive surveillance based on a regular follow-up schedule may result in early identification of these patients.

Repeated pulmonary metastasectomy has been found to offer a chance for long-term survival to patients with prolonged DFI after initial pulmonary metastasectomy [22], a solitary recurrent pulmonary lesion [23], and normal CEA level [17]. In addition, a recent meta-analysis reported a 5-year survival rate of 57.9% for patients who underwent repeated pulmonary metastasectomy [21], perhaps because these patients were highly selected, based on initial resection of PM. In our study a better prognosis was observed for patients with longer recurrent DFI than for patients with shorter recurrent DFI, whereas OS rate was not affected by treatment of recurrent PM with chemotherapy and surgical intervention. Therefore, repeated pulmonary metastasectomy in selected patients in whom the capacity of the remnant lung parenchyma could be preserved after resection may be a valuable alternative to palliative chemotherapy.

There was no definite consensus regarding recurrent DFI of recurrent PM, as DFI after the first pulmonary metastasectomy. Park et al. [17] reported that recurrent DFI was dichotomized before and after 12 months, whereas two other studies could not set the cut-off value of recurrent DFI, in which median recurrent DFI was 14 months (range, 4.0 to 29.0 months) and 16.8 months (range, 2.0 to 38.2 months), respectively [22,23]. Our results showed a median recurrent DFI of 13.0 months (range, 4.0 to 31.0 months). Therefore, we used the cut-off value of 12 months for recurrent DFI, as reported in a previous study [17].

Similar to the number of PMs, bilateral PM [6,22] and larger PM size [8] may indicate a greater likelihood of the presence of other undetectable metastatic lesions. However, in a previous study bilateral PM had no effect on OS [24], and most studies found no significant association between survival and PM size [19]. The current study found no association between these factors and survival rate. These findings suggest that bilateral PM and larger PM size that can be completely resected are not contraindications for pulmonary metastasectomy.

Several studies have reported better survival outcomes for patients with metachronous PM compared to those with synchronous PM, the latter being considered more aggressive [6]; however, it remains controversial [15]. In the current study, it did not appear that patients treated with metachronous PM had longer survival compared to those with synchronous PM, although patients with synchronous PM had more aggressive primary tumor stage, multiple PMs, and bilateral PMs. This might be due to the fact that only patients who underwent pulmonary metastasectomy for synchronous PM were included, because of the study limitation by retrospective design. Nevertheless, survival outcomes did not differ between patients who underwent pulmonary metastasectomy for synchronous PM and those who underwent pulmonary metastasectomy for metachronous PM. Therefore, pulmonary metastasectomy might be feasible in selected patients with either synchronous or metachronous PM.

Previous studies have reported on the usefulness of chest CT scan for detection of lung nodules, with > 70% sensitivity for detection of suspicious pulmonary metastatic nodules from CRC [25]. However, it does not appear to show correlation with an equal specificity, which may cause difficulty in interpreting the nature of a pulmonary lesion, because pathologic confirmation is too difficult or occasionally risky in most cases, particularly for small lesions. Therefore, we have used the regular follow-up program for patients with PM from CRC in accordance with National Comprehensive Cancer Network guidelines, and treatment decisions were made by the MDT.

This study had some limitations. First, there was a potential for selection bias, compounded by the retrospective design. Inclusion of patients was highly selective, with presumed good performance status, and fewer comorbidities, which might have contributed to the demonstrated long-term survival. Second, in this study chemotherapy after pulmonary metastasectomy did not appear to be significantly prognostic of OS, which may affect survival rate. Nevertheless, surgical resection of PM and recurrent PM after primary pulmonary metastasectomy was feasible for patients with or without systemic chemotherapy. In addition, we identified prognostic factors of survival in patients who underwent complete resection for metachronously developed PM, and divided them according to high- and low-risk groups using these factors. Further large-scale prospective studies will be helpful in verifying our results.

Conclusion

In conclusion, there is a potential survival benefit for patients with metachronous PM from CRC who undergo pulmonary metastasectomy, even those with recurrent pulmonary metastases. These findings suggest that pulmonary metastasectomy might benefit carefully selected patients, particularly those with longer DFI, solitary lesions, and absence of mediastinal LN involvement.

NOTES

Conflict of interest relevant to this article was not reported.

Acknowledgements

We thank the Medical Research Collaborating Center (MRCC) in Seoul National University Bundang Hospital for their kind assistance in the process of statistical analysis for this study.

Fig. 1.

Five-year overall survival (A) and disease-free survival (B) in the high- and low-risk groups. ^a)High-risk group was defined as patients with disease-free interval (DFI) < 12 months, or multiple pulmonary metastases, or mediastinal lymph node (LN) involvement, ^b)Low-risk group was defined as patients with DFI ≥ 12 months, solitary lesions, and absence of mediastinal LN involvement.

Table 1.

Patient characteristics

Characteristic	Total (n=176)	Synchronous PM (n=54)	Metachronous PM (n=122)	p-value
Age (yr)
≤ 60	85 (48.3)	30 (55.6)	55 (45.1)	0.25
> 60	91 (51.7)	24 (44.4)	67 (54.9)
Mean±SD	60.3±11.7	58.3±12.6	61.3±11.2	0.11
Sex
Male	114 (64.8)	31 (57.4)	83 (68.0)	0.23
Female	62 (35.2)	23 (42.6)	39 (32.0)
Body mass index (kg/m²)
≤ 25	131 (74.4)	43 (79.6)	88 (72.1)	0.35
< 25	45 (25.6)	11 (20.4)	34 (27.9)
Mean±SD	23.2±3.2	22.8±3.4	23.4±3.0	0.27
Primary tumor location
Colon	78 (44.3)	23 (42.6)	55 (45.1)	0.87
Rectum	98 (55.7)	31 (57.4)	67 (54.9)
Tumor stage^a)
1	7 (4.0)	2 (3.7)	5 (4.1)	< 0.001
2	26 (14.8)	2 (3.7)	24 (19.7)
3	86 (48.9)	14 (25.9)	72 (59.0)
4	57 (32.4)	36 (66.7)	21 (17.2)
Histology of primary tumor
Well differentiated	17 (9.7)	5 (9.3)	12 (9.8)	0.43
Moderately differentiated	149 (84.7)	44 (81.5)	105 (86.1)
Mucinous or poorly differentiated	10 (5.7)	5 (9.3)	5 (4.1)
Previous hepatectomy
No	151 (85.8)	43 (79.6)	108 (88.5)	0.16
Yes	25 (14.2)	11 (20.4)	14 (11.5)
Adjuvant therapy for CRC
No	14 (8.0)	9 (16.7)	5 (4.1)	0.01
Yes	162 (92.0)	45 (83.3)	117 (95.9)
No. of prior regimens
0	14 (8.0)	9 (16.7)	5 (4.1)	< 0.001
1	125 (71.0)	41 (75.9)	84 (68.9)
2	29 (16.5)	1 (1.9)	28 (23.0)
3	7 (4.0)	3 (5.6)	4 (3.3)
No data	1 (0.6)	0	1 (0.8)
Prior systemic chemotherapeutic agents
5-FU	131 (74.4)	43 (79.6)	88 (72.1)	-
Oxalipatin	95 (54.0)	26 (48.1)	69 (56.5)
Irinotecan	16 (9.1)	4 (7.4)	12 (9.8)
Capecitabine	56 (31.8)	14 (25.9)	42 (34.4)
Bevacizumab	11 (6.2)	4 (7.4)	7 (5.7)
Disease-free interval (mo)
< 12	75 (42.6)	54 (100)	21 (17.2)	< 0.001
≥ 12	101 (57.4)	0	101 (82.8)
Median (range)	13.0 (0-85)	0.0 (0-3)	22.0 (4-85)
No. of pulmonary tumors
Solitary	101 (57.4)	24 (44.4)	77 (63.1)	0.03
Multiple	75 (42.6)	30 (55.6)	45 (36.9)
Median (range)	1.0 (1-21)	2.0 (1-21)	1.0 (1-14)
Maximal tumor size (mm)
≤ 20	152 (86.4)	46 (85.2)	106 (86.9)	0.81
> 20	24 (13.6)	8 (14.8)	16 (13.1)
Median (range)	12.0 (2-70)	11.0 (3-60)	12.0 (2-70)
Distribution of metastases
Unilateral	144 (81.8)	36 (66.7)	108 (88.5)	0.01
Bilateral	32 (18.2)	18 (33.3)	14 (11.5)
Resection^b)
Non-anatomical	132 (75.0)	42 (77.8)	90 (73.8)	0.71
Anatomical	44 (25.0)	12 (22.2)	32 (26.2)
Mediastinal LN dissection
No	106 (60.2)	36 (66.7)	70 (57.4)	0.32
Yes	70 (39.8)	18 (33.3)	52 (42.6)
Mediastinal LN involvement
No	61 (34.7)	17 (31.5)	44 (36.1)	0.36
Yes	9 (5.1)	1 (1.9)	8 (6.6)
No data	106 (60.2)	36 (66.7)	70 (57.4)
Chemotherapy after metastasectomy
No	13 (7.4)	2 (3.7)	11 (9.0)	0.27
Cytotoxic agent only	139 (79.0)	42 (77.8)	97 (79.5)
Cytotoxic agent+targeted agent	24 (13.6)	10 (18.5)	14 (11.5)

Values are expressed as number (%) unless otherwise indicated. PM, pulmonary metastases; SD, standard deviation; CRC, colorectal cancer; 5-FU, 5-fluorouracil; LN, lymph node.

^a) Using the seventh edition of the American Joint Committee on Cancer staging system,

^b) Non-anatomical resection included precision excision and wedge resection; anatomical resection included segmental resection and lobectomy.

Table 2.

Univariable and multivariable analysis of factors prognostic of 5-year DFS after pulmonary metastasectomy

Characteristic	No. (n=122)	5-Yr DFS (%)	p-value	HR	95% CI	p-value
Age (yr)
≤ 60	55	49.4	0.23	-		-
> 60	67	50.0		-	-
Sex
Male	83	48.3	0.67	-		-
Female	39	57.7		-	-
Body mass index (kg/m²)
≤ 25	88	60.5	0.99	-		-
< 25	34	55.7		-	-
Primary tumor location
Colon	55	48.4	> 0.99	-		-
Rectum	67	53.2		-	-
Tumor stage^a)
1	5	66.7	0.08	-		-
2	24	74.3		-
3	72	49.4		-
4	21	29.9		-	-
Histology of primary tumor
Well differentiated	12	37.3	0.89	-		-
Moderately differentiated	105	52.8		-
Mucinous or poorly differentiated	5	53.3		-	-
Previous hepatectomy
No	108	53.8	0.12	-		-
Yes	14	23.4		-	-
Adjuvant therapy for CRC
No	5	100	0.10	-		-
Yes	117	49.0		-	-
Disease-free interval (mo)
< 12	21	25.8	0.01	1		0.01
≥ 12	101	55.8		0.298	0.149-0.598
No. of pulmonary tumors
Solitary	77	60.9	0.01	1		0.01
Multiple	45	34.4		2.451	1.285-4.674
Maximal tumor size (mm)
≤ 20	106	52.8	0.12	-		-
> 20	16	39.0		-	-
Distribution of metastases
Unilateral	108	54.5	0.01	1		0.97
Bilateral	14	23.8		1.014	0.418-2.463
Resection^b)
Non-anatomical	90	50.1	0.79	-		-
Anatomical	32	52.9		-	-
Mediastinal LN dissection
No	70	50.2	0.62	-		-
Yes	52	50.8		-	-
Mediastinal LN involvement
No	44	58.6	0.01	1		0.01
Yes	8	0.0		6.048	2.099-17.427	0.01
No data	70	50.2		1.014	0.418-2.463	0.58
Chemotherapy after PM
No	11	68.2	0.58	-		-
Cytotoxic agent only	97	58.0		-
Cytotoxic agent+targeted agent	14	60.0		-	-

DFS, disease-free survival; HR, hazard ratio; CI, confidence interval; CRC, colorectal cancer; LN, lymph node; PM, pulmonary metastasectomy.

^a) Using the seventh edition of the American Joint Committee on Cancer staging system,

^b) Non-anatomical resection included precision excision and wedge resection; anatomical resection included segmental resection and lobectomy.

Table 3.

Univariable and multivariable analysis of factors prognostic of 3-year OS following repeated pulmonary metastasectomy

Characteristic	No. (n=39)	3-Yr OS (%)	p-value	HR	95% CI	p-value
Age (yr)
≤ 60	20	44.1	0.40	-		-
> 60	19	64.4		-	-
Sex
Male	30	59.0	0.15	-		-
Female	9	41.7		-	-
BMI (kg/m²)
≤ 25	28	56.4	0.88	-		-
< 25	11	53.9		-	-
Primary tumor location
Colon	21	62.4	0.97	-		-
Rectum	18	48.7		-	-
Tumor stage of CRC
1	1	-	0.35	-		-
2	5	80.0		-
3	21	60.1		-
4	12	32.4		-	-
Histology of primary tumor
Well differentiated	4	50.0	0.34	-		-
Moderately differentiated	33	58.5		-
Mucinous or poorly differentiated	2	50.0		-	-
Previous hepatectomy
No	32	58.1	0.52	-		-
Yes	7	35.7		-	-
Recurrent DFI (mo)
< 12	14	32.7	0.01	1		0.01
≥ 12	25	70.5		0.252	0.084-0.757
No. of recurrent PM
Solitary	22	74.0	0.04	1		0.29
Multiple	17	29.1		1.977	0.563-6.943
Maximal tumor size of recurrent PM (mm)
≤ 20	30	59.4	0.38	-		-
> 20	9	44.4		-	-
Distribution of recurrent PM
Unilateral	35	64.1	0.01	1		0.48
Bilateral	4	25.0		1.663	0.407-6.787
Repeated resection
Non-anatomical	30	61.0	0.29	-		-
Anatomical	9	25.9		-	-
Mediastinal LN involvement
No	14	58.9	0.95	-		-
Yes	5	60.0		-
No data	20	51.0		-	-
Chemotherapy after PM
No	3	66.7	0.49	-		-
Cytotoxic agent only	31	58.9		-
Cytotoxic agent+targeted agent	5	30.0		-	-

OS, overall survival; HR, hazard ratio; CI, confidence interval; BMI, body mass index; CRC, colorectal cancer; DFI, disease free interval; PM, pulmonary metastases; LN, lymph node.

Table 4.

Comparison of clinical characteristics in the high- and low-risk subgroups

Characteristic	High-risk group^a) (n=70)	Low-risk group^b) (n=52)	p-value
Age (yr)
≤ 60	34 (48.6)	21 (40.4)	0.46
> 60	36 (51.4)	31 (59.6)
Mean±SD	60.5±11.2	62.3±11.1	0.38
Sex
Male	48 (68.6)	35 (67.3)	> 0.99
Female	22 (31.4)	17 (32.7)
BMI (kg/m²)
≤ 25	50 (71.4)	38 (73.1)	> 0.99
< 25	20 (28.6)	14 (26.9)
Mean±SD	23.3±3.2	23.6±2.9	0.61
Primary tumor location
Colon	34 (48.6)	21 (40.4)	0.46
Rectum	36 (51.4)	31 (59.6)
Tumor stage of CRC
1-3	50 (71.4)	48 (92.3)	0.01
4	20 (28.6)	4 (7.7)
Histology of primary tumor
Well	6 (8.6)	6 (11.5)	0.14
Moderately	59 (84.3)	46 (88.5)
Mucinous or poorly	5 (7.1)	0
Previous hepatectomy
No	58 (82.9)	50 (96.2)	0.02
Yes	12 (17.1)	2 (3.8)
Adjuvant therapy for CRC
No	2 (2.9)	3 (5.8)	0.65
Yes	68 (97.1)	49 (94.2)
DFI (mo)
< 12	21 (30.0)	0	< 0.001
≥ 12	49 (70.0)	52 (100)
Median (range)	15.0 (4-83)	28.0 (13-85)
No. of pulmonary tumors
Solitary	25 (35.7)	52 (100)	< 0.001
Multiple	45 (64.3)	0
Median (range)	2.0 (1-14)	1.0
Maximal tumor size (mm)
≤ 20	58 (82.9)	48 (92.3)	0.18
> 20	12 (17.1)	4 (7.7)
Median (range)	13.5 (2-70)	10.0 (3-38)
Distribution of metastases
Unilateral	56 (80.0)	52 (100)	< 0.001
Bilateral	14 (20.0)	0
Resection
Non-anatomical	51 (72.9)	39 (75.0)	0.84
Anatomical	19 (27.1)	13 (25.0)
Mediastinal LN involvement^c)
No	27 (77.1)	17 (100)	0.04
Yes	8 (22.9)	0
Recurrent PM
No	32 (45.7)	42 (80.8)	< 0.001
Yes	38 (54.3)	10 (19.2)

Values are presented as number (%) unless otherwise indicated. SD, standard deviation; BMI, body mass index; CRC, colorectal cancer; DFI, disease-free interval; LN, lymph node; PM, pulmonary metastases.

^a) High-risk group was defined as patients with DFI < 12 months, or multiple PM, or mediastinal LN involvement,

^b) Low-risk group was defined as patients with DFI ≥ 12 months, solitary lesions, and absence of mediastinal LN involvement,

^c) Including 52 patients who underwent mediastinal LN dissection.

REFERENCES

1. Gatta G, Faivre J, Capocaccia R, Ponz de Leon M. Survival of colorectal cancer patients in Europe during the period 1978-1989. EUROCARE Working Group. Eur J Cancer. 1998;34:2176–83. Article PubMed
2. Zink S, Kayser G, Gabius HJ, Kayser K. Survival, disease-free interval, and associated tumor features in patients with colon/rectal carcinomas and their resected intra-pulmonary metastases. Eur J Cardiothorac Surg. 2001;19:908–13. Article PubMed
3. August DA, Ottow RT, Sugarbaker PH. Clinical perspective of human colorectal cancer metastasis. Cancer Metastasis Rev. 1984;3:303–24. Article PubMed
4. McCormack PM, Burt ME, Bains MS, Martini N, Rusch VW, Ginsberg RJ. Lung resection for colorectal metastases: 10-year results. Arch Surg. 1992;127:1403–6. Article PubMed
5. Iwasaki A, Shirakusa T, Yamashita Y, Noritomi T, Maekawa T, Hamada T. Characteristic differences between patients who have undergone surgical treatment for lung metastasis or hepatic metastasis from colorectal cancer. Thorac Cardiovasc Surg. 2005;53:358–64. Article PubMed
6. Inoue M, Ohta M, Iuchi K, Matsumura A, Ideguchi K, Yasumitsu T, et al. Benefits of surgery for patients with pulmonary metastases from colorectal carcinoma. Ann Thorac Surg. 2004;78:238–44. Article PubMed
7. Girard P, Ducreux M, Baldeyrou P, Rougier P, Le Chevalier T, Bougaran J, et al. Surgery for lung metastases from colorectal cancer: analysis of prognostic factors. J Clin Oncol. 1996;14:2047–53. Article PubMed
8. Vogelsang H, Haas S, Hierholzer C, Berger U, Siewert JR, Prauer H. Factors influencing survival after resection of pulmonary metastases from colorectal cancer. Br J Surg. 2004;91:1066–71. Article PubMed
9. Simmonds PC. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group. BMJ. 2000;321:531–5. Article PubMed PMC
10. Seymour MT, Stenning SP, Cassidy J. Attitudes and practice in the management of metastatic colorectal cancer in Britain. Colorectal Cancer Working Party of the UK Medical Research Council. Clin Oncol (R Coll Radiol). 1997;9:248–51. Article PubMed
11. National Comprehensive Cancer Network. NCCN guidelines version 3. Colon Cancer [Internet]. Fort Washington, PA: National Comprehensive Cancer Network; 2013. [cited 2012 Nov 26]. Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp
12. Wolpin BM, Mayer RJ. Systemic treatment of colorectal cancer. Gastroenterology. 2008;134:1296–310. Article PubMed PMC
13. Saito Y, Omiya H, Kohno K, Kobayashi T, Itoi K, Teramachi M, et al. Pulmonary metastasectomy for 165 patients with colorectal carcinoma: a prognostic assessment. J Thorac Cardiovasc Surg. 2002;124:1007–13. Article PubMed
14. Rena O, Casadio C, Viano F, Cristofori R, Ruffini E, Filosso PL, et al. Pulmonary resection for metastases from colorectal cancer: factors influencing prognosis: twenty-year experience. Eur J Cardiothorac Surg. 2002;21:906–12. Article PubMed
15. Mitry E, Guiu B, Cosconea S, Jooste V, Faivre J, Bouvier AM. Epidemiology, management and prognosis of colorectal cancer with lung metastases: a 30-year population-based study. Gut. 2010;59:1383–8. Article PubMed
16. Cho S, Song IH, Yang HC, Jheon S. Prognostic factors of pulmonary metastasis from colorectal carcinoma. Interact Cardiovasc Thorac Surg. 2013;17:303–7. Article PubMed PMC
17. Park JS, Kim HK, Choi YS, Kim K, Shim YM, Jo J, et al. Outcomes after repeated resection for recurrent pulmonary metastases from colorectal cancer. Ann Oncol. 2010;21:1285–9. Article PubMed
18. Simmonds PC, Primrose JN, Colquitt JL, Garden OJ, Poston GJ, Rees M. Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer. 2006;94:982–99. Article PubMed PMC
19. Pfannschmidt J, Dienemann H, Hoffmann H. Surgical resection of pulmonary metastases from colorectal cancer: a systematic review of published series. Ann Thorac Surg. 2007;84:324–38. Article PubMed
20. Sakamoto T, Tsubota N, Iwanaga K, Yuki T, Matsuoka H, Yoshimura M. Pulmonary resection for metastases from colorectal cancer. Chest. 2001;119:1069–72. Article PubMed
21. Salah S, Watanabe K, Park JS, Addasi A, Park JW, Zabaleta J, et al. Repeated resection of colorectal cancer pulmonary oligometastases: pooled analysis and prognostic assessment. Ann Surg Oncol. 2013;20:1955–61. Article PubMed
22. Chen F, Sakai H, Miyahara R, Bando T, Okubo K, Date H. Repeat resection of pulmonary metastasis is beneficial for patients with colorectal carcinoma. World J Surg. 2010;34:2373–8. Article PubMed
23. Welter S, Jacobs J, Krbek T, Krebs B, Stamatis G. Long-term survival after repeated resection of pulmonary metastases from colorectal cancer. Ann Thorac Surg. 2007;84:203–10. Article PubMed
24. Riquet M, Foucault C, Cazes A, Mitry E, Dujon A, Le Pimpec Barthes F, et al. Pulmonary resection for metastases of colorectal adenocarcinoma. Ann Thorac Surg. 2010;89:375–80. Article PubMed
25. Murata K, Takahashi M, Mori M, Kawaguchi N, Furukawa A, Ohnaka Y, et al. Pulmonary metastatic nodules: CT-pathologic correlation. Radiology. 1992;182:331–5. Article PubMed

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

circEIF3I Promotes Colorectal Cancer Metastasis by Regulating the miR‐328‐3p/NCAPH Axis
Yali Zhao, Yan He, Zhiyuan Xiao, Le Xin, Mingjing Deng, Mingxia Yao, Guan Huang
Molecular Carcinogenesis.2025; 64(3): 450. CrossRef
Role of Pulmonary Metastasectomy in Colorectal Cancer
Zamaan Hooda, Michael Eisenberg, Mara B. Antonoff
Thoracic Surgery Clinics.2025; 35(2): 143. CrossRef
Outcomes and prognostic factors of repeat pulmonary metastasectomy
Ryu Kanzaki, Hirokazu Watari, Akiisa Omura, Sachi Kawagishi, Ryo Tanaka, Tomohiro Maniwa, Jiro Okami
Interdisciplinary CardioVascular and Thoracic Surgery.2024;[Epub] CrossRef
Development of a protocol for whole-lung in vivo lung perfusion-assisted photodynamic therapy using a porcine model
Khaled Ramadan, Tina Saeidi, Edson Brambate, Vanderlei Bagnato, Marcelo Cypel, Lothar Lilge
Journal of Biomedical Optics.2024;[Epub] CrossRef
Preoperative prognostic factors for 5-year survival following pulmonary metastasectomy from colorectal cancer: a systematic review and meta-analysis
Andreas Gkikas, Christos Kakos, Savvas Lampridis, Peter J Godolphin, Davide Patrini
European Journal of Cardio-Thoracic Surgery.2023;[Epub] CrossRef
FUT2 inhibits the EMT and metastasis of colorectal cancer by increasing LRP1 fucosylation
Lingnan He, Zijun Guo, Weijun Wang, Shuxin Tian, Rong Lin
Cell Communication and Signaling.2023;[Epub] CrossRef
PET/MRI in colorectal and anal cancers: an update
Vetri Sudar Jayaprakasam, Semra Ince, Garima Suman, Pankaj Nepal, Thomas A. Hope, Raj Mohan Paspulati, Tyler J. Fraum
Abdominal Radiology.2023; 48(12): 3558. CrossRef
A review of surgery for lung metastasis from colorectal cancer
Yu-Kwang Lee, Mong-Wei Lin, Ke-Cheng Chen, Pei-Ming Huang, Shuenn-Wen Kuo, Jang-Ming Lee
Formosan Journal of Surgery.2023;[Epub] CrossRef
Long-term outcomes and early recurrence after resection for metachronous pulmonary metastases from colorectal cancer
Shintaro Hashimoto, Tetsuro Tominaga, Takashi Nonaka, Keisuke Noda, Soishiro Kiya, Toshio Shiraishi, Kaido Oishi, Yuma Takamura, Shoto Yamazaki, Masato Araki, Yorihisa Sumida, Takuro Miyazaki, Ryotaro Kamohara, Shigeyuki Morino, Keitaro Matsumoto, Akihiro
Langenbeck's Archives of Surgery.2023;[Epub] CrossRef
Survival and prognostic factors of isolated pulmonary metastases originating from colorectal cancer: An 8-year single-center experience
Ameera S. Balhareth, Abdullah S. AlQattan, Hassan M. Alshaqaq, Abdullah M. Alkhalifa, Alaa A. Al Abdrabalnabi, Muna S. Alnamlah, Deborah MacNamara
Annals of Medicine and Surgery.2022; 77: 103559. CrossRef
Long term survival after multiple microwave ablations for colorectal cancer lung metastases: A case report
Victoria T. Y Lee, Yueh-Hsin Lin, Derek Glenn, Suhrid Lodh, David L. Morris
Radiology Case Reports.2022; 17(6): 2038. CrossRef
A model to assess acute and delayed lung toxicity of oxaliplatin during in vivo lung perfusion
Khaled Ramadan, Bruno Gomes, Mauricio Pipkin, Mariola Olkowicz, Barbara Bojko, Arnaud Romeo Mbadjeu Hondjeu, Shaf Keshavjee, Thomas Waddell, Janusz Pawliszyn, Marcelo Cypel
The Journal of Thoracic and Cardiovascular Surgery.2021; 161(5): 1626. CrossRef
Prognostic value of KRAS mutation in patients undergoing pulmonary metastasectomy for colorectal cancer: A systematic review and meta-analysis
Junfeng Huang, Qing Zang, Yaokai Wen, Zhe Pan, Zhiyuan Yao, Mingkai Huang, Jiongqiang Huang, Jingsong Chen, Rongchang Wang
Critical Reviews in Oncology/Hematology.2021; 160: 103308. CrossRef
Systematic Review of Treatments for Colorectal Metastases in Elderly Patients to Guide Surveillance Cessation Following Hepatic Resection for Colorectal Liver Metastases
Edward Alabraba, Dhanny Gomez
American Journal of Clinical Oncology.2021; 44(5): 210. CrossRef
Determination of Optical Properties and Photodynamic Threshold of Lung Tissue for Treatment Planning of In Vivo Lung Perfusion Assisted Photodynamic Therapy
Khaled T. Ramadan, Christopher McFadden, Bruno Gomes, Fynn Schwiegelshohn, Rafaela V.P. Ribeiro, Harley H.L. Chan, Vaughn Betz, Marcelo Cypel, Lothar Lilge
Photodiagnosis and Photodynamic Therapy.2021; 35: 102353. CrossRef
Survival outcome of pulmonary metastasectomy among the patients with colorectal cancers
Oya Yıldız, Shute Ailia Dae, Alper Fındıkcıoglu, Fatih Kose
Revista da Associação Médica Brasileira.2021; 67(7): 1015. CrossRef
Circular RNA circHERC4 as a novel oncogenic driver to promote tumor metastasis via the miR-556-5p/CTBP2/E-cadherin axis in colorectal cancer
Jiehua He, Ziqiang Chu, Wei Lai, Qiusheng Lan, Yujie Zeng, Daning Lu, Shaowen Jin, Heyang Xu, Pengwei Su, Dong Yin, Zhonghua Chu, Lu Liu
Journal of Hematology & Oncology.2021;[Epub] CrossRef
Vaccines for colorectal cancer: an update
Mostafa Sarvizadeh, Faezeh Ghasemi, Fatemeh Tavakoli, Sara Sadat Khatami, Ebrahim Razi, Hossein Sharifi, Nousin Moussavi Biouki, Mohsen Taghizadeh
Journal of Cellular Biochemistry.2019; 120(6): 8815. CrossRef
Surgical management of colorectal lung metastases
Joseph D. Phillips, Rian M. Hasson
Journal of Surgical Oncology.2019; 119(5): 629. CrossRef
Chemotherapy for resected colorectal cancer pulmonary metastases: Utilization and outcomes in routine clinical practice
S. Karim, S. Nanji, K. Brennan, C.S. Pramesh, C.M. Booth
European Journal of Surgical Oncology (EJSO).2017; 43(8): 1481. CrossRef
The characteristics and outcomes of small bowel adenocarcinoma: a multicentre retrospective observational study
Hiroyuki Sakae, Hiromitsu Kanzaki, Junichiro Nasu, Yutaka Akimoto, Kazuhiro Matsueda, Masao Yoshioka, Masahiro Nakagawa, Shinichiro Hori, Masafumi Inoue, Tomoki Inaba, Atsushi Imagawa, Masahiro Takatani, Ryuta Takenaka, Seiyu Suzuki, Toshiyoshi Fujiwara,
British Journal of Cancer.2017; 117(11): 1607. CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Curative Resection for Metachronous Pulmonary Metastases from Colorectal Cancer: Analysis of Survival Rates and Prognostic Factors

Cancer Res Treat. 2017;49(1):104-115. Published online May 9, 2016

DOI: https://doi.org/10.4143/crt.2015.367

XML Download

Abstract
Introduction
Materials and Methods
Results
Discussion
Conclusion
NOTES
REFERENCES

Curative Resection for Metachronous Pulmonary Metastases from Colorectal Cancer: Analysis of Survival Rates and Prognostic Factors

Fig. 1. Five-year overall survival (A) and disease-free survival (B) in the high- and low-risk groups. a)High-risk group was defined as patients with disease-free interval (DFI) < 12 months, or multiple pulmonary metastases, or mediastinal lymph node (LN) involvement, b)Low-risk group was defined as patients with DFI ≥ 12 months, solitary lesions, and absence of mediastinal LN involvement.

Fig. 1.

Curative Resection for Metachronous Pulmonary Metastases from Colorectal Cancer: Analysis of Survival Rates and Prognostic Factors

Characteristic	Total (n=176)	Synchronous PM (n=54)	Metachronous PM (n=122)	p-value
Age (yr)
≤ 60	85 (48.3)	30 (55.6)	55 (45.1)	0.25
> 60	91 (51.7)	24 (44.4)	67 (54.9)
Mean±SD	60.3±11.7	58.3±12.6	61.3±11.2	0.11
Sex
Male	114 (64.8)	31 (57.4)	83 (68.0)	0.23
Female	62 (35.2)	23 (42.6)	39 (32.0)
Body mass index (kg/m²)
≤ 25	131 (74.4)	43 (79.6)	88 (72.1)	0.35
< 25	45 (25.6)	11 (20.4)	34 (27.9)
Mean±SD	23.2±3.2	22.8±3.4	23.4±3.0	0.27
Primary tumor location
Colon	78 (44.3)	23 (42.6)	55 (45.1)	0.87
Rectum	98 (55.7)	31 (57.4)	67 (54.9)
Tumor stage^a)
1	7 (4.0)	2 (3.7)	5 (4.1)	< 0.001
2	26 (14.8)	2 (3.7)	24 (19.7)
3	86 (48.9)	14 (25.9)	72 (59.0)
4	57 (32.4)	36 (66.7)	21 (17.2)
Histology of primary tumor
Well differentiated	17 (9.7)	5 (9.3)	12 (9.8)	0.43
Moderately differentiated	149 (84.7)	44 (81.5)	105 (86.1)
Mucinous or poorly differentiated	10 (5.7)	5 (9.3)	5 (4.1)
Previous hepatectomy
No	151 (85.8)	43 (79.6)	108 (88.5)	0.16
Yes	25 (14.2)	11 (20.4)	14 (11.5)
Adjuvant therapy for CRC
No	14 (8.0)	9 (16.7)	5 (4.1)	0.01
Yes	162 (92.0)	45 (83.3)	117 (95.9)
No. of prior regimens
0	14 (8.0)	9 (16.7)	5 (4.1)	< 0.001
1	125 (71.0)	41 (75.9)	84 (68.9)
2	29 (16.5)	1 (1.9)	28 (23.0)
3	7 (4.0)	3 (5.6)	4 (3.3)
No data	1 (0.6)	0	1 (0.8)
Prior systemic chemotherapeutic agents
5-FU	131 (74.4)	43 (79.6)	88 (72.1)	-
Oxalipatin	95 (54.0)	26 (48.1)	69 (56.5)
Irinotecan	16 (9.1)	4 (7.4)	12 (9.8)
Capecitabine	56 (31.8)	14 (25.9)	42 (34.4)
Bevacizumab	11 (6.2)	4 (7.4)	7 (5.7)
Disease-free interval (mo)
< 12	75 (42.6)	54 (100)	21 (17.2)	< 0.001
≥ 12	101 (57.4)	0	101 (82.8)
Median (range)	13.0 (0-85)	0.0 (0-3)	22.0 (4-85)
No. of pulmonary tumors
Solitary	101 (57.4)	24 (44.4)	77 (63.1)	0.03
Multiple	75 (42.6)	30 (55.6)	45 (36.9)
Median (range)	1.0 (1-21)	2.0 (1-21)	1.0 (1-14)
Maximal tumor size (mm)
≤ 20	152 (86.4)	46 (85.2)	106 (86.9)	0.81
> 20	24 (13.6)	8 (14.8)	16 (13.1)
Median (range)	12.0 (2-70)	11.0 (3-60)	12.0 (2-70)
Distribution of metastases
Unilateral	144 (81.8)	36 (66.7)	108 (88.5)	0.01
Bilateral	32 (18.2)	18 (33.3)	14 (11.5)
Resection^b)
Non-anatomical	132 (75.0)	42 (77.8)	90 (73.8)	0.71
Anatomical	44 (25.0)	12 (22.2)	32 (26.2)
Mediastinal LN dissection
No	106 (60.2)	36 (66.7)	70 (57.4)	0.32
Yes	70 (39.8)	18 (33.3)	52 (42.6)
Mediastinal LN involvement
No	61 (34.7)	17 (31.5)	44 (36.1)	0.36
Yes	9 (5.1)	1 (1.9)	8 (6.6)
No data	106 (60.2)	36 (66.7)	70 (57.4)
Chemotherapy after metastasectomy
No	13 (7.4)	2 (3.7)	11 (9.0)	0.27
Cytotoxic agent only	139 (79.0)	42 (77.8)	97 (79.5)
Cytotoxic agent+targeted agent	24 (13.6)	10 (18.5)	14 (11.5)

Characteristic	No. (n=122)	5-Yr DFS (%)	p-value	HR	95% CI	p-value
Age (yr)
≤ 60	55	49.4	0.23	-		-
> 60	67	50.0		-	-
Sex
Male	83	48.3	0.67	-		-
Female	39	57.7		-	-
Body mass index (kg/m²)
≤ 25	88	60.5	0.99	-		-
< 25	34	55.7		-	-
Primary tumor location
Colon	55	48.4	> 0.99	-		-
Rectum	67	53.2		-	-
Tumor stage^a)
1	5	66.7	0.08	-		-
2	24	74.3		-
3	72	49.4		-
4	21	29.9		-	-
Histology of primary tumor
Well differentiated	12	37.3	0.89	-		-
Moderately differentiated	105	52.8		-
Mucinous or poorly differentiated	5	53.3		-	-
Previous hepatectomy
No	108	53.8	0.12	-		-
Yes	14	23.4		-	-
Adjuvant therapy for CRC
No	5	100	0.10	-		-
Yes	117	49.0		-	-
Disease-free interval (mo)
< 12	21	25.8	0.01	1		0.01
≥ 12	101	55.8		0.298	0.149-0.598
No. of pulmonary tumors
Solitary	77	60.9	0.01	1		0.01
Multiple	45	34.4		2.451	1.285-4.674
Maximal tumor size (mm)
≤ 20	106	52.8	0.12	-		-
> 20	16	39.0		-	-
Distribution of metastases
Unilateral	108	54.5	0.01	1		0.97
Bilateral	14	23.8		1.014	0.418-2.463
Resection^b)
Non-anatomical	90	50.1	0.79	-		-
Anatomical	32	52.9		-	-
Mediastinal LN dissection
No	70	50.2	0.62	-		-
Yes	52	50.8		-	-
Mediastinal LN involvement
No	44	58.6	0.01	1		0.01
Yes	8	0.0		6.048	2.099-17.427	0.01
No data	70	50.2		1.014	0.418-2.463	0.58
Chemotherapy after PM
No	11	68.2	0.58	-		-
Cytotoxic agent only	97	58.0		-
Cytotoxic agent+targeted agent	14	60.0		-	-

Characteristic	No. (n=39)	3-Yr OS (%)	p-value	HR	95% CI	p-value
Age (yr)
≤ 60	20	44.1	0.40	-		-
> 60	19	64.4		-	-
Sex
Male	30	59.0	0.15	-		-
Female	9	41.7		-	-
BMI (kg/m²)
≤ 25	28	56.4	0.88	-		-
< 25	11	53.9		-	-
Primary tumor location
Colon	21	62.4	0.97	-		-
Rectum	18	48.7		-	-
Tumor stage of CRC
1	1	-	0.35	-		-
2	5	80.0		-
3	21	60.1		-
4	12	32.4		-	-
Histology of primary tumor
Well differentiated	4	50.0	0.34	-		-
Moderately differentiated	33	58.5		-
Mucinous or poorly differentiated	2	50.0		-	-
Previous hepatectomy
No	32	58.1	0.52	-		-
Yes	7	35.7		-	-
Recurrent DFI (mo)
< 12	14	32.7	0.01	1		0.01
≥ 12	25	70.5		0.252	0.084-0.757
No. of recurrent PM
Solitary	22	74.0	0.04	1		0.29
Multiple	17	29.1		1.977	0.563-6.943
Maximal tumor size of recurrent PM (mm)
≤ 20	30	59.4	0.38	-		-
> 20	9	44.4		-	-
Distribution of recurrent PM
Unilateral	35	64.1	0.01	1		0.48
Bilateral	4	25.0		1.663	0.407-6.787
Repeated resection
Non-anatomical	30	61.0	0.29	-		-
Anatomical	9	25.9		-	-
Mediastinal LN involvement
No	14	58.9	0.95	-		-
Yes	5	60.0		-
No data	20	51.0		-	-
Chemotherapy after PM
No	3	66.7	0.49	-		-
Cytotoxic agent only	31	58.9		-
Cytotoxic agent+targeted agent	5	30.0		-	-

Characteristic	High-risk group^a) (n=70)	Low-risk group^b) (n=52)	p-value
Age (yr)
≤ 60	34 (48.6)	21 (40.4)	0.46
> 60	36 (51.4)	31 (59.6)
Mean±SD	60.5±11.2	62.3±11.1	0.38
Sex
Male	48 (68.6)	35 (67.3)	> 0.99
Female	22 (31.4)	17 (32.7)
BMI (kg/m²)
≤ 25	50 (71.4)	38 (73.1)	> 0.99
< 25	20 (28.6)	14 (26.9)
Mean±SD	23.3±3.2	23.6±2.9	0.61
Primary tumor location
Colon	34 (48.6)	21 (40.4)	0.46
Rectum	36 (51.4)	31 (59.6)
Tumor stage of CRC
1-3	50 (71.4)	48 (92.3)	0.01
4	20 (28.6)	4 (7.7)
Histology of primary tumor
Well	6 (8.6)	6 (11.5)	0.14
Moderately	59 (84.3)	46 (88.5)
Mucinous or poorly	5 (7.1)	0
Previous hepatectomy
No	58 (82.9)	50 (96.2)	0.02
Yes	12 (17.1)	2 (3.8)
Adjuvant therapy for CRC
No	2 (2.9)	3 (5.8)	0.65
Yes	68 (97.1)	49 (94.2)
DFI (mo)
< 12	21 (30.0)	0	< 0.001
≥ 12	49 (70.0)	52 (100)
Median (range)	15.0 (4-83)	28.0 (13-85)
No. of pulmonary tumors
Solitary	25 (35.7)	52 (100)	< 0.001
Multiple	45 (64.3)	0
Median (range)	2.0 (1-14)	1.0
Maximal tumor size (mm)
≤ 20	58 (82.9)	48 (92.3)	0.18
> 20	12 (17.1)	4 (7.7)
Median (range)	13.5 (2-70)	10.0 (3-38)
Distribution of metastases
Unilateral	56 (80.0)	52 (100)	< 0.001
Bilateral	14 (20.0)	0
Resection
Non-anatomical	51 (72.9)	39 (75.0)	0.84
Anatomical	19 (27.1)	13 (25.0)
Mediastinal LN involvement^c)
No	27 (77.1)	17 (100)	0.04
Yes	8 (22.9)	0
Recurrent PM
No	32 (45.7)	42 (80.8)	< 0.001
Yes	38 (54.3)	10 (19.2)

Table 1. Patient characteristics

Values are expressed as number (%) unless otherwise indicated. PM, pulmonary metastases; SD, standard deviation; CRC, colorectal cancer; 5-FU, 5-fluorouracil; LN, lymph node.

Using the seventh edition of the American Joint Committee on Cancer staging system,

Non-anatomical resection included precision excision and wedge resection; anatomical resection included segmental resection and lobectomy.

Table 2. Univariable and multivariable analysis of factors prognostic of 5-year DFS after pulmonary metastasectomy

DFS, disease-free survival; HR, hazard ratio; CI, confidence interval; CRC, colorectal cancer; LN, lymph node; PM, pulmonary metastasectomy.

Using the seventh edition of the American Joint Committee on Cancer staging system,

Non-anatomical resection included precision excision and wedge resection; anatomical resection included segmental resection and lobectomy.

Table 3. Univariable and multivariable analysis of factors prognostic of 3-year OS following repeated pulmonary metastasectomy

OS, overall survival; HR, hazard ratio; CI, confidence interval; BMI, body mass index; CRC, colorectal cancer; DFI, disease free interval; PM, pulmonary metastases; LN, lymph node.

Table 4. Comparison of clinical characteristics in the high- and low-risk subgroups

High-risk group was defined as patients with DFI < 12 months, or multiple PM, or mediastinal LN involvement,

Low-risk group was defined as patients with DFI ≥ 12 months, solitary lesions, and absence of mediastinal LN involvement,